[A25-71 ] Selpercatinib (RET mutant medullary thyroid cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 10.10.2025
Project no.:
A25-71
Commission:
Commission awarded on 28.05.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults and adolescents 12 years and older with advanced rearranged during transfection-mutant medullary thyroid cancer; first-line therapy
Indication of major added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2025-09-01.
https://doi.org/10.60584/A25-71_V1.1